Home › Funds › Sanofi › NVAX

Sanofi position in NVAX

Novavax · Health Care

Sanofi reported holding 6,880,481 shares of NVAX (Novavax) in its Q3 2026 13F filing — a position valued at US$74.4M, representing 11.81% of its reported portfolio and ranking #3 among its reported holdings. Sanofi has disclosed NVAX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)6.88M sh
Reported value held$74.38M
Portfolio Weight11.81%
First reportedQ4 2024
Last changeHold
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's NVAX position evolved

Sanofi first disclosed a stake in NVAX in Q4 2024 at 6,880,481 shares (US$55.3M). The position peaked in Q3 2026 at 6,880,481 shares, worth US$74.4M. Across 8 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 6,880,481 shares valued at US$74.4M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 6.88M $55.32M New
Q1 2025 6.88M $44.10M Hold
Q2 2025 6.88M $43.35M Hold
Q3 2025 6.88M $59.65M Hold
Q4 2025 6.88M $46.24M Hold
Q1 2026 6.88M $56.01M Hold
Q2 2026 6.88M $64.81M Hold
Q3 2026 6.88M $74.38M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NVAX and 13F data

NVAX (Novavax) is a Health Care company. 26 other funds we track also report a position in NVAX — the largest reported positions include SHAH CAPITAL MANAGEMENT (US$131.6M), Coatue Management (US$36.1M), COATUE MANAGEMENT LLC (US$36.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NVAX

All NVAX fund holders →

FAQ

How long has Sanofi held NVAX?

Sanofi has disclosed NVAX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Sanofi's current position in NVAX?

As of Q3 2026, Sanofi holds 6.88M shares of NVAX (Novavax), valued at $74.38M, representing 11.81% of its reported portfolio and ranking #3.

Has Sanofi been buying or selling NVAX?

In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in NVAX. The position peaked in Q3 2026 at 6.88M shares.

Which other funds hold NVAX?

Other major institutional holders of NVAX include SHAH CAPITAL MANAGEMENT, Coatue Management, COATUE MANAGEMENT LLC, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.